Global Lewy Body Dementia Treatment Market, By Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Antidepressants, Benzodiazepine, Modafinil), Application Type (Parkinson’s Disease, Alzheimer’s Disease), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Lewy Body Dementia Treatment Market Analysis and Size
Lewy Body Dementia (LBD) affects people mostly aged 50 years and above. It accounts for about 1-2% of all the cases of dementia. Lewy body is also projected to be found in other neurological disorders such as Parkinson’s disease and Alzheimer’s disease. Furthermore, underdiagnosis and late diagnosis of this disease in the elderly population is likely to impede the treatment for the same.
Data Bridge Market Research analyses a growth rate in the lewy body dementia treatment market in the forecast period 2023-2030. The expected CAGR of lewy body dementia treatment market is tend to be around 8.30% in the mentioned forecast period. The market value is USD 5233.5 million in 2022, and it would grow up to USD 9904.2 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lewy Body Dementia Treatment Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Antidepressants, Benzodiazepine, Modafinil), Application Type (Parkinson’s Disease, Alzheimer’s Disease), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Amneal Pharmaceuticals LLC. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Abbott (U.S.) B Braun SE (Germany), Integra LifeSciences (U.S.), Johnson & Johnson Services, Inc. (India), Medtronic (Ireland), MicroPort Scientific Corporation (China), NuVasive, Inc (U.S.), Orthofix US LLC (U.S.), Perrigo Company plc. (Ireland), Stryker (U.S.), Zimmer Biomet (U.S.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.)
The lewy body dementia (LBD) is a type of disorder where abnormal sediments known as alpha-synuclein are found in the brain. The sediments, called Lewy bodies, affect the chemical transmission in the brain. There are some changes that would lead to problems in loss of cognitive skills, difficulty in movement and behavior. One of the major causes because of which dementia is caused is lewy body dementia. The symptoms start early and worsen in the later part. This disease causes a decline in mental abilities leading to numerous symptoms such as rigid muscles, visual hallucinations, tremors, and slow movement. Other symptoms include cognitive problems, poor regulation of body functions, sleep difficulties, and depression.
Lewy Body Dementia Treatment Market Dynamics
- Increase in Elderly Population
Increase in elderly population and presence of major market players are launching the drugs for managing dementia condition. According to the research, around 40% of Parkinson’s patients are most likely to suffer from Parkinson’s dementia disease after the age of 60 years. Furthermore, in China, the elderly population is projected to increase by 30% by 2040. This is anticipated to boost the demand for efficient treatment of LBD during the forecast period 2023-2030.
- Increased Agreements and Acquisitions from Several Market Players
There has been different agreements and collaborations between market players that lead to the growth of the market. For instance, Biogen Inc. agreed to buy PF-05251749 in January 2020 from Pfizer Inc. to treat patients with behavioral and neurological symptoms in a range of psychiatric and neurological illnesses. Biogen wants to develop the Phase 1 asset (PD) for sundowning in Alzheimer's Disease (AD) and Irregular Sleep-Wake Rhythm Disorder (ISWRD). Furthermore, Proteostasis Therapeutics, Inc. and Yumanity Therapeutics signed a definitive merger agreement in August 2020 and the combined company is named as Yumanity Therapeutics, Inc. The aim is to improve its pipeline of new, disease-modifying approaches and solutions for several neurological illnesses.
- Growing Treatment Methods
There are several treatment methods that are helpful in boosting the growth of the market. Benzodiazepine is used to treat insomnia, anxiety, and seizures. This type of drug is mainly used for short-term treatment. The most common type used is Xanax. There are some antidepressants that are used to treat anxiety disorders, chronic pain, eating disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). They work by rising levels of certain chemicals in the brain that help to improve mood. Then there are antipsychotic drugs that are used to treat many mental disorders such as schizophrenia. These drugs work by stopping some chemicals in the brain that may lead to psychotic symptoms. Another drug called arbidopa-levodopa is a prescription medication used to treat Parkinson's disease and parkinsonism. Carbidopa helps to prevent the breakdown of levodopa before it reaches the brain. Thus, all these treatment methods are boosting the growth of the market.
- High Cost of Treatment
The vast expenditure required for the varied treatment processes hinders market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to improve the recovery process, and in return, the cost is increased. Thus, this hampers the market growth.
- Late Diagnosis of Elderly Population
The lewy body dementia is commonly seen in aged people. The underdiagnosis and late diagnosis of lewy body dementia in the elderly population is most likely to impede the treatment for the same. Additionally, there is no proper cure for this condition, which further restricts the market growth.
This lewy body dementia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lewy body dementia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Lewy Body Dementia Treatment Market Scope
The lewy body dementia treatment market is segmented on the basis of drug type, application type, mode of purchase and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Cholinesterase Inhibitors
- Antipsychotic Drugs
- Parkinson’s Disease
- Alzheimer’s Disease
Mode of Purchase
- Over the Counter
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
Lewy Body Dementia Treatment Regional Analysis/Insights
The lewy body dementia treatment market is analyzed and market size insights and trends are provided by drug type, application type, mode of purchase and distribution channel as referenced above.
The major countries covered in the lewy body dementia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market in the forecast period because of the increase in patient population suffering from lewy body dementia, Parkinson’s disease, the increase in elderly population, high awareness among the population base, and the increased affordability of oral medications.
Asia-Pacific is considered to grow over the coming years because of ongoing R&Dfor the treatment of lewy body dementia, untreated neurological conditions, and many opportunities in developing markets.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Lewy Body Dementia Treatment Share Analysis
The lewy body dementia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lewy body dementia treatment market
Key players operating in the lewy body dementia treatment market include:
- Amneal Pharmaceuticals LLC. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Merck & Co Inc. (U.S.)
- Abbott (U.S.)
- B Braun SE (Germany)
- Integra LifeSciences (U.S.)
- Johnson & Johnson Services, Inc. (India)
- Medtronic (Ireland)
- MicroPort Scientific Corporation (China)
- NuVasive, Inc (U.S.)
- Orthofix US LLC (U.S.)
- Perrigo Company plc. (Ireland)
- Stryker Corporation (U.S.)
- Zimmer Biomet (U.S.)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)